Taxane-resistant lymphoepithelial-like carcinoma: Excellent response to VIP chemotherapy

• DOI: 10.1007/bf03169176
• Publication Date: 2013-12-04T10:44:10Z
• Authors: A. G. Duffy; G. Wyse; A. M. Morgan; M. O’Keefe; S. O’Reilly; O. S. Breathnach
• Keywords: Adult; Bridged-Ring Compounds; Male; Muscle Neoplasms; Carcinoma; Antineoplastic Agents; 3. Good health; Radiography; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Drug Resistance, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Humans; Taxoids; Ifosfamide; Cisplatin; Podophyllotoxin; Psoas Muscles

Lymphoepithelial-like carcinoma is a rare tumour type. The optimal treatment for this disease is not known. No effective therapies are described in the literature.This report describes a case of lymphoepithelial-like carcinoma and documents a therapeutic strategy which has proved effective.The patient was initially treated with a common platinum-based chemotherapy regimen incorporating a taxane (Carbplatin and Docetaxel). Disease stabilization initially occurred but the patient soon progressed. The patient was then treated with VIP chemotherapy and had a complete response.VIP chemotherapy appears to be an effective therapeutic strategy in lymphoepithelial-like carcinoma.